Still, no one on Wall Street is expecting Lilly to collapse. Some analysts say Lilly is on the right track and could bounce back in a few years. Lilly stock has remained in the mid- to high 30s for most of the past two years, although that's down from the 50s four years ago.
"It's going to be a challenge for Lilly, but survivability is not a question," said Linda Bannister, a drug analyst at Edward Jones and Co. in St. Louis, who has a "hold" rating on the stock. "They have some interesting things in the pipeline, and if they are successful, Lilly could be a growth company again."
The company has about 70 experimental drugs under development. They include about 10 in late-stage clinical testing for serious ailments such as Alzheimer's disease (a medicine called solanezumab), depression (NERI), cancer (ramucirumab), schizophrenia (mGlu2/3 pro) and diabetes (BI 10773).
It's been more than a decade since Lilly went through such a financial upheaval. In 2001, the company found itself in a crisis when it suddenly lost patent exclusivity on Prozac, its best-selling antidepressant, which accounted for 34 percent of the company's sales.
Monday, October 03, 2011
21: days of protection left for Lilly's Zyprexa | The Indianapolis Star | indystar.com